Latest Humira Dispute Highlights Biosimilar Trade Secrets Dangers

Director Paul A. Ainsworth was quoted in the article “Latest Humira Dispute Highlights Biosimilar Trade Secrets Dangers,” published by IAM. From the article:

“It is also crucial for all biosimilar businesses to take steps to avoid falling foul of trade secrets protections, comments Sterne Kessler’s Paul Ainsworth: ‘Companies that hire people who previously worked on a product that they want to bring to market need to take extra steps to ensure that they are not creating a problem, even if they have no intention of misappropriating secrets.’ Businesses should be clear in their hiring processes about their expectation that former employers’ information should not be used, Ainsworth comments.”